Active 0 6 0 6 O
cytomegalovirus 7 22 7 22 B-chronic_disease
disease 23 30 23 30 I-chronic_disease

Active 0 6 31 37 B-chronic_disease
varicella 7 16 38 47 I-chronic_disease
zoster 17 23 48 54 I-chronic_disease
infection 24 33 55 64 I-chronic_disease

Adult 0 5 65 70 O
lung 6 10 71 75 B-treatment
transplant 11 21 76 86 I-treatment
recipients 22 32 87 97 O
â‰¥ 33 34 98 99 O
18 35 37 100 102 B-lower_bound
years 38 43 103 108 I-lower_bound
of 44 46 109 111 O
age 47 50 112 115 B-age
who 51 54 116 119 O
meet 55 59 120 124 O
the 60 63 125 128 O
diagnostic 64 74 129 139 O
criteria 75 83 140 148 O
for 84 87 149 152 O
AMR 88 91 153 156 O
and 92 95 157 160 O
who 96 99 161 164 O
have 100 104 165 169 O
underwent 105 114 170 179 O
PFT 115 118 180 183 O
testing 119 126 184 191 O
unless 127 133 192 198 O
intubated 134 143 199 208 O
and 144 147 209 212 O
transbronchial 148 162 213 227 B-treatment
biopsy 163 169 228 234 I-treatment
prior 170 175 235 240 O
to 176 178 241 243 O
enrollment 179 189 244 254 O

Breastfeeding 0 13 255 268 O
women 14 19 269 274 B-gender

Concurrent 0 10 275 285 O
use 11 14 286 289 O
of 15 17 290 292 O
another 18 25 293 300 O
proteasome 26 36 301 311 B-treatment
inhibitor 37 46 312 321 I-treatment
( 47 48 322 323 O
e.g. 48 52 323 327 O
, 52 53 327 328 O
bortezomib 54 64 329 339 B-treatment
) 64 65 339 340 O

Direct 0 6 341 347 O
contraindications 7 24 348 365 O
or 25 27 366 368 O
previous 28 36 369 377 O
intolerances 37 49 378 390 O
to 50 52 391 393 O
any 53 56 394 397 O
component 57 66 398 407 O
of 67 69 408 410 O
the 70 73 411 414 O
standard 74 82 415 423 O
of 83 85 424 426 O
care 86 90 427 431 O
regimen 91 98 432 439 O
including 99 108 440 449 O
PLEX 109 113 450 454 B-clinical_variable
, 113 114 454 455 O
5 115 116 456 457 B-upper_bound
% 116 117 457 458 I-upper_bound
human 118 123 459 464 B-clinical_variable
albumin 124 131 465 472 I-clinical_variable
, 131 132 472 473 O
5 133 134 474 475 O
% 134 135 475 476 O
gammagard 136 145 477 486 B-clinical_variable
S 146 147 487 488 I-clinical_variable
/ 147 148 488 489 I-clinical_variable
D 148 149 489 490 I-clinical_variable
or 150 152 491 493 O
10 153 155 494 496 B-upper_bound
% 155 156 496 497 I-upper_bound
gammagard 157 166 498 507 B-clinical_variable
liquid 167 173 508 514 I-clinical_variable

Known 0 5 515 520 O
Child 6 11 521 526 O
- 11 12 526 527 O
Pugh 12 16 527 531 O
B 17 18 532 533 O
/ 18 19 533 534 O
C 19 20 534 535 O
cirrhosis 21 30 536 545 B-chronic_disease

Known 0 5 546 551 O
pulmonary 6 15 552 561 B-chronic_disease
hypertension 16 28 562 574 I-chronic_disease

Known 0 5 575 580 O
systolic 6 14 581 589 B-chronic_disease
heart 15 20 590 595 I-chronic_disease
failure 21 28 596 603 I-chronic_disease
with 29 33 604 608 O
LVEF 34 38 609 613 B-clinical_variable
< 39 40 614 615 O
40 41 43 616 618 B-upper_bound
% 43 44 618 619 I-upper_bound

Leukopenia 0 10 620 630 B-chronic_disease

Neutropenia 0 11 631 642 B-chronic_disease

Ongoing 0 7 643 650 O
bacterial 8 17 651 660 B-chronic_disease
or 18 20 661 663 O
fungal 21 27 664 670 B-chronic_disease
or 28 30 671 673 O
viral 31 36 674 679 B-chronic_disease
infection 37 46 680 689 I-chronic_disease
that 47 51 690 694 O
is 52 54 695 697 O
life 55 59 698 702 O
- 59 60 702 703 O
threatening 60 71 703 714 O

Pregnant 0 8 715 723 B-pregnancy
women 9 14 724 729 B-gender

Previous 0 8 730 738 O
intolerance 9 20 739 750 O
to 21 23 751 753 O
carfilzomib 24 35 754 765 B-treatment

Thrombocytopenia 0 16 766 782 B-chronic_disease

